Sangamo Therapeutics Appoints Prathyusha Duraibabu as Senior Vice President, Effective June 1, 2021
May 24, 2021 at 04:15 pm EDT
Share
Sangamo Therapeutics, Inc. announced the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. Ms. Duraibabu joined Sangamo in March 2019 with over 20 years of experience and has built out the financial planning and analysis, controllership, audit, procurement, and compliance teams and functions. Prior to joining Sangamo, Ms. Duraibabu served as the Corporate Controller at Pacific Biosciences.
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
SANGAMO THERAPEUTICS, INC. 
